Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Western China real-world PEG-rhGH cohort study in children with growth hormone deficiency
ChiCTR2400093194Phase 4Not yet recruiting
- Sponsor
- Chengdu Women's and Children's Central Hospital
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peg-somatropin in growth hormone deficiency (GHD), sponsored by Chengdu Women's and Children's Central Hospital. Primary endpoint: Height. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
peg-somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on ChiCTR2400093194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093194.